SIRT2 and breast carcinoma: Moreover, cellular assays in MCF-7 breast cancer cells revealed that ST132 has shown an antiproliferative effect, as well as increased acetylated α-tubulin expression levels, which is typically consistent with SIRT2 inhibition.